Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sundrug CoTSE:9989 +1.34%75 EBIT per Share is 円394.86 as of Mar. 2026. GuruFocus rates TSE:9989 with a GF Score™ of 75/100 and a GF Value™ of 円4,741.32 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 526 Healthcare Providers & Services companies, Sundrug Co ranks worse than 56.46% on this metric.
Sundrug Co's EBIT per Share for the
three
months ended in Mar. 2026 was 円85.22.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円394.86.
During the past 12 months, the average EBIT per Share Growth Rate of Sundrug Co was 5.20% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 7.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 6.00% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 3.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Sundrug Co's EBIT per Share or its related term are showing as below:
TSE:9989'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -14.2 Med: 6.2 Max: 42.1
Current: 7.7
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Sundrug Co was 42.10% per year. The lowest was -14.20% per year. And the median was 6.20% per year.
TSE:9989's 3-Year EBIT Growth Rate is ranked worse than 56.46% of 526
companies
in the Healthcare Providers & Services industry
Industry Median: 11.95
vs TSE:9989: 7.70
Sundrug Co's EBIT for the
three
months ended in Mar. 2026 was 円9,969 Mil.
Sundrug Co (TSE:9989) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Sundrug Co EBIT per Share Related Terms
Sundrug Co EBIT per Share Historical Data
* Premium members only.
The historical data trend for Sundrug Co's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円394.86
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sundrug Co (TSE:9989) has a EBIT per Share of 円394.86 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sundrug Co and its competitors. According to the industry distribution chart, Sundrug Co ranks #297 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 56.5%.
Is Sundrug Co's EBIT per Share too high?
Sundrug Co's current EBIT per Share is 円394.86. Based on the distribution chart, Sundrug Co ranks #297 out of 526 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Sundrug Co has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sundrug Co's EBIT per Share compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Sundrug Co ranks #297 out of 526 companies for EBIT per Share. This places Sundrug Co in the lower half of its industry. The industry median EBIT per Share is 11.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 11.95, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sundrug Co and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 11.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sundrug Co's current EBIT per Share is 円394.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sundrug Co stock overvalued right now?
Based on GuruFocus' analysis, Sundrug Co (TSE:9989) is currently considered Modestly Undervalued. The stock's GF Value™ is 円4,741.32, compared to a current price of 円3,867.00 — trading 18.4% below its estimated fair value. The current EBIT per Share is 円394.86. Sundrug Co's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Sundrug Co (TSE:9989), the current EBIT per Share is 円394.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sundrug Co (TSE:9989) Overvalued in 2026?
Based on GuruFocus' analysis, Sundrug Co stock appears to be undervalued.
The current stock price of 円3,867.00 is trading 18.4% below its estimated GF Value™ of 円4,741.32.
GuruFocus considers Sundrug Co to be Modestly Undervalued.
Key valuation signals for TSE:9989:
EBIT per Share: 円394.86
GF Value™: 円4,741.32 vs. price of 円3,867.00 (18.4% below fair value)
No single metric tells the full story. See the TSE:9989 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sundrug Co Ltd is a Japanese-based company engaged in the operation of drug stores and discount stores. The Group operates through two segments: the Drug Store Business, which mainly sells pharmaceuticals, cosmetics, and daily necessities, and the Discount Store Business, which mainly sells food products, household goods, and other related items. It generates the majority of its revenue from the Drugstore business segment.
75GF Score
Get the complete analysis for TSE:9989
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:9989 has been successfully added to your 
